Is CASI Pharmaceuticals, Inc. (CASI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 688.7% / 30% | 500.5% / 30% | 477.3% / 30% | 1.89% / 5% | ✗ NOT HALAL |
| DJIM | 688.7% / 33% | 500.5% / 33% | 477.3% / 33% | 1.89% / 5% | ✗ NOT HALAL |
| MSCI | 41.3% / 33% | 30.0% / 33% | 28.6% / 33% | 1.89% / 5% | ✗ NOT HALAL |
| S&P | 688.7% / 33% | 500.5% / 33% | 477.3% / 33% | 1.89% / 5% | ✗ NOT HALAL |
| FTSE | 41.3% / 33% | 30.0% / 33% | 28.6% / 50% | 1.89% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 35.8% | |
| Operating Margin | -333.1% | |
| Net Margin | -184.0% | |
| Return on Assets (ROA) | -61.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$29M |
| Total Debt | $22M |
| Current Ratio | 0.3 |
| Total Assets | $54M |
Price & Trading
| Last Close | $0.00 |
| 50-Day MA | $0.82 |
| 200-Day MA | $1.38 |
| Avg Volume | 56K |
| Beta | 0.9 |
|
52-Week Range
$0.21
| |
About CASI Pharmaceuticals, Inc. (CASI)
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CASI Pharmaceuticals, Inc. (CASI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CASI Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CASI Pharmaceuticals, Inc.'s debt ratio?
CASI Pharmaceuticals, Inc.'s debt ratio is 688.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 41.3%.
What are CASI Pharmaceuticals, Inc.'s key financial metrics?
CASI Pharmaceuticals, Inc. has a market capitalization of $3M, and revenue of $29M. The company maintains a gross margin of 35.8% and a net margin of -184.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.